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You might as well question why we breathe. 
If we stop breathing, we’ll die. 
If we stop fighting our enemies, 
the world will die. 
Victor Laszlo in Casablanca
  
ABSTRACT 
The air we inhale contains oxygen necessary for life, but also potentially harmful 
microorganisms, toxins and allergens. This presents an important immunological 
dilemma: how can our lungs quickly and selectively eliminate harmful agents without 
inflicting damage on the delicate tissues of the lungs? We have thus evolved a 
network of cells involved in immune surveillance, made up of dendritic cells (DCs), 
monocytes and macrophages. Together, these mononuclear phagocytes sample the 
lungs and airways for presence of foreign pathogens such as viruses or bacteria. 
Recognition of pathogenic patterns – for instance the genetic material of viruses or 
the lipid membrane of bacteria – triggers a cascade of events in these immune cells. 
They produce inflammatory mediators to signal that a source of danger has been 
detected, and to contain the infection while awaiting the arrival of other immune cells. 
DCs migrate to lymphoid organs where they present antigens to naïve T cells, thus 
shaping the generation of protective and adaptive immunity. Much of what we know 
of how our immune system functions come from studies in murine models.  
In this thesis, we focus our attention on human DCs. Using super resolution 
microscopy, we assessed the early trafficking events that take place upon 
internalisation of influenza A virus (IAV) by human DCs. We report that IAV trafficked 
via early and late endosomes in DCs, similar to epithelial cells, but with more 
delayed kinetics. Next, we investigated whether maturation of monocyte-derived 
versus bona fide DCs affects their susceptibility to IAV infection. Indeed, the two 
subsets of DCs are inherently different in their ability to respond to pathogenic 
signals by producing antiviral mediators, which protect them from IAV infection. The 
accessibility of human blood has improved our understanding of human DCs. 
However, immune cells residing at mucosal barriers are our first line of defence 
against respiratory viruses. Increasing data suggest that there is tissue-specific 
regulation of immune cells due to factors present in the local microenvironment. 
Hence, we performed bronchoscopies on healthy subjects and hantavirus-infected 
patients to characterise DCs residing in the airways and bronchial mucosal tissue. 
We identified several subsets of respiratory DCs at steady state, alongside alveolar 
macrophages and monocyte-derived cells. During acute hantavirus disease, DCs 
and monocytes were depleted from circulation, whereas the lungs were infiltrated 
with monocytes and DCs.    
Collectively, our findings reveal the heterogeneity of human DCs in their response to 
respiratory viruses, depending on their origin and anatomical location. A deeper 
understanding of the complex interplay between respiratory viruses and human DCs 
reveals how DCs contribute to immunity or pathogenesis. This knowledge may help 
us develop better preventive and therapeutic strategies by targeting or modulating 
DCs to achieve favourable immune responses.   
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This thesis is a documentation of research conducted in support of my doctoral 
degree (PhD). In the past four years, my colleagues and I have dedicated our time 
and effort in investigating the role of human dendritic cells, an important player in our 
immune system, in defending us against respiratory viruses such as influenza virus 
and hantavirus. The thesis can be broadly divided into two sections: 
In the first section, I will provide an overview into the field of human immunology, by 
introducing basic concepts of immunity and inflammation that is hopefully accessible 
to all readers. I will then define the general aim of this thesis and the specific aims of 
the four studies included. Finally, I will explore our existing knowledge of the topic by 
delving deeper into our understanding of dendritic cells and also the close 
relationship with monocytes and macrophages, with details on their history, origins 
and roles. An overview of the respiratory viruses responsible for causing diseases 
will also be presented, with details on their molecular structure and life cycle and the 
immune responses mounted against the viruses. 
In the second section, I will describe the materials and methods used throughout the 
papers included in the thesis. I will then highlight the key findings of each study and 
provide an analysis of their implications in the context of existing literature. Finally, I 
will summarise the main conclusions of this thesis and speculate the future 
directions of where the studies may continue moving forward, followed by reprints of 
the original papers. 
 
Faezzah Baharom    September 2016, Stockholm 
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1 INTRODUCTION 
Immunology is the study of our body’s immune system, evolved to protect us against 
various threats. The origin of these threats can be foreign, such as invading bacteria 
and viruses called pathogens, or self, such as cancers or damaged cells from injury. 
In the late 18th century, Edward Jenner demonstrated the concept of immunity; 
getting cowpox, a mild disease, can be protective against the more deadly 
smallpox1. This laid the foundation for modern vaccination, where healthy individuals 
are inoculated with weakened pathogens to prevent disease. Seminal studies by 
Louis Pasteur and Robert Koch further established the “germ theory”: specific 
microorganisms cause infectious diseases2,3. To protect ourselves against disease-
causing pathogens, our body is trained to mount an immune response. This is a 
highly coordinated process that can be divided into 4 main tasks: 1) identify the 
threat, 2) eliminate the threat, 3) avoid collateral damage to harmless bystanders, 
and 4) remember the threat.  
The human respiratory tract is organised like a tree with a trachea that branches into 
airways terminating in millions of vascularised alveoli, the site of gas exchange. The 
total surface area of healthy human lungs is approximately 90 m2; a massive area 
exposed to the external environment4. Hence, the lungs need to be poised to 
respond to invading pathogens. The airways can filter out virus particles in inhaled 
air via nasal hairs and mucous layers that trap the virus particles thus preventing 
virus binding and attachment to host cells. However when the viruses penetrate the 
mucous layer, immune cells need to be able to detect the breach in physical defence 
and retaliate against the invading pathogens (Figure 1).  
 
Figure 1. Initiation of immune responses in the lungs against respiratory threats. Innate 
immune cells such as dendritic cells (DCs) and alveolar macrophages reside in the airways to 
sample incoming pathogens, allergens or toxins. During inflammation, more monocytes and DCs 
infiltrate the lungs from circulation. Mature DCs migrate to draining lymph nodes via the afferent 
lymphatic vessels where they present antigens to naïve T cells. Antigen-specific T cells exit via the 
efferent lymphatic vessels and home to the site of infection. Lung illustration modified from Servier 
Medical Art. 
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Viruses are small, obligate parasites that are entirely dependent on their host cell for 
survival5,6. They carry their own genetic material, but cannot replicate without using 
the machinery of their host7. Influenza A virus (IAV) and hantavirus are the main 
threats that are in focus in this thesis due to their ability to cause disease and even 
death in humans. IAV causes the seasonal flu, or the occasional but more severe 
pandemic flu. Hantaviruses can cause haemorrhagic fever with renal syndrome 
(HFRS) or hantavirus pulmonary syndrome (HPS) depending on the viral strain. The 
respiratory tract acts as an entry point of these viruses into their human host. IAV 
infection typically manifests within the upper airways, whereas hantaviruses first 
replicate in the lungs but can then enter the blood circulation and be detected in 
various other organs. 
The innate immune response is readily available to detect and respond to a wide 
range of pathogens without developing long lasting memory8. Innate immune cells 
include monocytes, macrophages and dendritic cells (DCs), key players of our innate 
immunity that will be the focus of this thesis, but also granulocytes, mast cells and 
natural killer (NK) cells. These cells recognise pathogen-associated molecular 
patterns (PAMPs) via receptors such as Toll-like receptors (TLRs). Activation of 
TLRs trigger the production of specific proteins called cytokines and chemokines, 
and chemical factors such as histamines and prostaglandins, which mediate 
inflammation. While individual innate immune cells play different roles, they can all 
contribute to inflammation, clinically recognised as the development of fever, pain, 
swelling and ache. Inflammation is an important response to an infection, as it 
triggers the permeability of blood vessels so that more immune cells can enter the 
site of infection from the blood. However, a dysregulated immune response can lead 
to exaggerated inflammation that is harmful to surrounding, healthy cells.  
In contrast, the adaptive immune response is specific and long lasting9. The key 
players in our adaptive immunity include B cells, responsible for generating 
antibodies against specific pathogens, and T cells, subdivided into CD4+ T helper 
cells (Th) or CD8+ T cells that develop into cytotoxic T lymphocyte (CTLs), killing 
infected cells directly. As professional antigen presenting cells (APCs), DCs that 
patrol the peripheral tissues acquire antigens (e.g. small fragments of a pathogen) 
and present them to B and T cells on receptors called major histocompatibility 
complex (MHC). This specific interaction between an antigen-MHC complex and the 
B cell or T cell receptor, gives effector cells the licence to produce antibodies or 
attack infected cells. CTLs can also be harmful if not carefully regulated, hence 
negative feedback and immunosuppressive mediators are an important aspect of 
how our immune system can function properly.  
Now, 220 years after Edward Jenner experimented on a healthy eight-year-old boy 
to discover smallpox vaccine, stricter ethical guidelines have been put in place for 
conducting modern day research, in order to protect human volunteers from abuse. 
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The Declaration of Helsinki established in 1964 requires that human research be 
based on results from laboratory animals10. As a consequence, the focus of 
immunological research has shifted to using inbred mouse models. This led to a 
wider range of tools to manipulate different aspects of the immune system, resulting 
in many important discoveries. Among others, DCs were discovered in the spleen of 
mice with the unique ability to activate naïve T cells11. Important fate mapping 
studies in mice have also dissected the origin of different immune cell populations12. 
However, a reliance on mouse models to study the immune response against 
infectious diseases may have skewed our understanding of human immune 
responses that are ultimately most critical in developing effective human vaccines. 
Misinformation can also be dangerous, as we have learnt from the anti-CD28 clinical 
trials on six healthy human volunteers, resulting in massive cytokine storms and 
multi-organ failure that was not predicted in animal studies13. This reaffirms the need 
for more translational studies in humans to overcome the discrepancies between the 
immune system of animal models and of humans. Although mechanistic insights 
may be limited in human immunology studies, they can complement important 
findings in mice in a more correlative manner.  
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2 AIMS OF THESIS 
The general aim of this thesis was to better understand how DCs, equipped to 
detect, capture and present viruses to other immune cells, are involved during 
respiratory viral infections in humans. The specific objectives were as follows: 
 
• To study the early trafficking events of IAV upon internalisation by human DCs, 
using super resolution imaging (Paper I), 
 
• To assess how prior exposure to pathogenic signals induces maturation and 
affects the susceptibility of different subsets of human DCs to infection by IAV 
(Paper II), 
 
• To characterise the phenotype and function of monocytes and DCs in blood and 
airways at steady state (Paper III), 
 
• To investigate the impact of hantavirus infection on monocytes and DCs in blood 
and lung mucosal tissue during acute and convalescent phases of disease in 
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3 DENDRITIC CELLS, MONOCYTES & MACROPHAGES 
3.1 BRIEF HISTORY OF MONONUCLEAR PHAGOCYTES 
3.1.1 Discovery of mononuclear phagocytes 
Mononuclear phagocytes (MNPs) refer to an umbrella term including DCs, 
monocytes and macrophages. They form a heterogeneous population of cells that 
excel in taking up antigens for destruction, or for processing and presentation to 
initiate and regulate immune responses14. The capacity of DCs to regulate immune 
responses have made them attractive targets for vaccination, cancer 
immunotherapy, antiviral therapy and treatment of autoimmune/inflammatory 
diseases15-17. 
The term mononuclear phagocytes was first coined in the 1960s by van Furth, 
referring to both circulating monocytes and tissue macrophages18, as opposed to the 
other group of polymorphonuclear phagocytes (granulocytes)19, but their history 
dates further back. In the 1880s, the concept of phagocytosis (from ancient Greek, 
meaning “to devour”) was established by the Nobel Laureate Elie Metchnikoff, who 
described the ability of macrophages to engulf foreign entities as a defence 
mechanism20. Following labelling studies using radioactive thymidine, monocytes 
were defined as precursors of macrophages circulating in blood as has been 
extensively studied by van Furth and others. In 1973, the Nobel Laureate Ralph 
Steinman discovered a novel type of “dendritic-shaped cell that can process and 
present antigen to activate naïve T cells" in the spleen of mice, calling them DCs in 
his seminal papers11,21-23. DCs then joined monocytes and macrophages as another 
member of the mononuclear phagocyte system. 
3.1.2 Relationship between DCs, monocytes and macrophages 
More recently, there has been a paradigm shift in our understanding of the 
relationship between DCs, monocytes and macrophages. For decades since their 
discovery, DCs and macrophages were thought to be functional variations of 
monocytes. This was supported by the ease in which monocytes can be skewed to 
behave like DCs or macrophages in vitro24-27, depending on the culture conditions, 
and also in vivo during inflammation28-31. 
However, more careful lineage studies in mice have identified haematopoietic 
precursors to DCs (called committed DC progenitors, CDPs) that are distinct from 
monocytes (Figure 2)32-34. Monocytes are derived from a different progenitor (called 
common monocyte progenitor, cMop)35. These observations in mice have also been 
confirmed in humans following the identification of DC precursors in circulation, cord 
blood and bone marrow36,37. Another paradigm-shifting discovery is that tissue-
resident macrophages are not exclusively derived from circulating monocytes, as 
has been the dogma following van Furth’s findings in the 1960s. Instead, tissue-
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resident macrophages can develop from embryonic precursors such as yolk sac 
macrophages or fetal liver monocytes12,38-44. In short, there is mounting evidence to 
suggest that monocytes, DCs and macrophages are not developmental 
progressions from one cell type to another, but instead originate from distinct 
precursors.  
 
The matter is complicated by the plasticity of monocytes that can acquire different 
functional properties shared by macrophages and DCs, depending on the 
inflammatory environment45,46. Identification of cell types based purely on expression 
of surface markers or functional specialisation presents a challenge as several 
different populations share the same receptors, and subsets can acquire or lose 
functional capacities during inflammation47. Beyond semantics, the definition of cell 
populations is important for interpretation and translation of findings between 
different groups, especially when specific functional attributes are assigned to 
distinct populations. A shift towards complementing phenotypic identification with 
transcriptional profiling has allowed a better separation of DCs, monocytes and 
macrophages, including a better alignment of cells across tissues and species. The 
important contributions of individual cell populations can then be carefully elucidated, 
to improve our understanding of immunopathogenesis or to be able to design better 
vaccine/therapeutic strategies targeting specific MNPs. 
Figure 2. The embryonic and haematopoietic development of mononuclear phagocytes.  
Monocytes, DCs and macrophages originate from distinct lineages, with monocytes and DCs 
originating from haematopoietic stem cell (HSC) precursors, whereas some tissue macrophages 
have an embryonic origin. They are also differentially dependent on various growth factors and 
express different transcription factors critical to their development. 
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3.2 SUBSETS AND FUNCTIONS 
3.2.1 Ontogeny 
The ontogeny of DCs refers to both the origin from their precursors, and the 
development pathways resulting in functional DCs. Classification of cell populations 
based on their ontogeny has been proposed by several experts in the field as a 
consistent and robust way to distinguish bona fide DCs from monocytes and 
macrophages, allowing us to understand their specific roles during health and 
disease46. 
Experiments in murine models relying on adoptive transfer of specific precursors to 
irradiated animals have defined DCs as a separate haematopoietic lineage34,48. 
Briefly, their lineage begins in the bone marrow from haematopoietic stem cells 
(HSCs) in the following sequential order of increasingly restricted progenitors: 
common myeloid progenitor (CMPs), monocyte-macrophage DC progenitors 
(MDPs), common DC progenitor, and finally PDCs or pre-classical DCs (cDCs) that 
can differentiate to either cDC1 (CD141+ MDCs in humans) or cDC2 (CD1c+ MDCs 
in humans). Maintenance of DC development is linked to their expression of Fms-
like tyrosine kinase 3 (FLT3) and their ability to respond to FLT3 ligand49,50. 
In parallel, monocytes diverge at the MDP stage where they form common monocyte 
progenitors (cMop) with the potential to develop into monocytes and monocyte-
derived macrophages, relying on the cytokine CSF-1. As briefly discussed before, 
the origin of tissue-resident macrophages is more heterogeneous, as they can arise 
from yolk sac macrophages, fetal liver monocytes or bone marrow monocytes, 
depending on the tissue51. 
Translation of these findings to human DC ontogeny has been difficult, but a 
combination of comparative transcriptomics analyses, clinical observations and in 
vitro culture models support the observations in mice. Cross-species transcriptomic 
studies suggest that PDCs, CD1c+ DCs and CD141+ DCs represent bona fide DCs 
as they are homologous to well-defined mice PDCs, CD11b+ DCs and CD8+/CD103+ 
DCs respectively52-59. Patients undergoing haematopoietic stem cell transplantation 
have been valuable to study the kinetics and turnover of DCs in tissues60. Further, 
patients lacking GATA2 and IRF8 are deficient for all DC subsets in their blood, 
suggesting a common precursor that is missing61,62.  Finally, several recent studies 
have advanced the DC field by mapping human myeloid precursors that closely 
resemble those found in mice bone marrow and blood36,37 (Figure 3).  In human cord 
blood and bone marrow, human granulocyte-monocyte-DC progenitors (hGMP), 
human monocyte-DC progenitors (hMDP) and human common DC progenitors were 
identified, with increasingly restricted capacity to generate specific cell populations37. 
In blood, a migratory precursor giving rise to only CD1c+ and CD141+ MDCs were 
identified36. 
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3.2.2 Cell surface markers 
Defining DCs based on ontogeny presents a challenge in humans, in the absence of 
amendable genetic studies to deplete entire lineages. Hence, cell surface markers 
continue to be a reliable source of information for classification of DCs, monocytes 
and macrophages based on their phenotype, preferably supported by transcriptomic 
and functional analyses. Recent comparative studies have attempted to unify the 
MNP populations between mice and humans. The cell surface markers used to 
identify and sort out individual populations of MNPs are summarised in Figure 4. A 
common gating strategy used by our group and several others to identify DCs in 
blood and tissue is by first gating on all haematopoietic cells (CD45+), excluding all 
lineage cells (monocytes, B cells, T cells, NK cells and neutrophils) and then gating 
on cells expressing the MHC class II molecule, HLA-DR+ cells to identify DCs63,64. 
CD11c can be used to distinguish myeloid DCs from plasmacytoid DCs. Aside from 
peripheral blood, all three populations have also been identified in human bone 
marrow, skin, gut, lungs, liver, spleen, lymph nodes and tonsils52,55,64-68. However, 
the precise phenotype of DCs in human tissue, such as the lungs, continues to be 
investigated and debated upon. The most studied tissue in humans is the skin69,70. 
Most recently, Guilliams et al. propose a framework to standardise the identification 
of DCs in human tissues at steady state and during inflammation71.  
In human blood, three populations of monocytes have been described based on their 
differential expression of CD14 and CD16: classical monocytes, intermediate 
monocytes and non-classical monocytes72. In mice, monocytes under non-inflamed 
conditions can extravasate constitutively into tissues while retaining their monocytic 
character41. It is still unclear if, in humans, all three monocyte populations present in 
blood can extravasate into tissues, and whether they remain undifferentiated, or 
differentiate into macrophages/DCs. In the human airways, CD14+CD16+ cells are a 
major population of MNPs, forming a third of all HLA-DR+lineage- cells, excluding 
Figure 3. Schematic displaying the sequential origin of human DCs from myeloid 
progenitors.  In vitro culture models recapitulate in vivo DC hematopoiesis employing progenitors 
from human cord blood and bone marrow; human granulocyte-monocyte-DC progenitor (hGMP), 
human monocyte-DC progenitor (hMDP), human common DC progenitor (hCDP) and human 
migratory precursor (hprec-DC). 
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alveolar macrophages64. In peripheral tissues, phenotypic analysis is complicated by 
the presence of monocyte-derived cells with overlapping cell surface markers that 
exhibit features of DCs or macrophages. CD14+ cells in the skin have previously 
been thought to be an additional DC population, but recent transcriptomic and 
functional analysis suggested that these cells are distinct from the DC lineage, 
instead resembling monocyte-derived macrophages73. Similar careful 
characterisation of CD14+ cells described in human lungs64,65, would be valuable to 
understand whether these are tissue monocytes, monocyte-derived DCs or 
monocyte-derived macrophages. A better definition of DCs, monocytes and 
macrophage populations will also help to translate important findings across different 
research groups. 
 
Figure 4. Phenotype of human MNPs and their homologues in mice. Human MNPs (left 
column) in blood have been well characterised, while tissue MNPs are still being carefully 
investigated. Distinct markers for lung or blood MNPs are indicated by lung or blood symbols. 
Homologues in mice are indicated in the right column whereas conserved markers expressed by 
both species are indicated in the middle column.  
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3.2.3 Functional properties 
The variety of MNPs play distinct but overlapping roles in the induction/regulation of 
immunity, including antigen uptake, processing and presentation, and cytokine 
production74.  
3.2.3.1 Antigen capture by endocytosis 
Endocytosis is a constitutive process performed by all cells for the uptake of a wide 
variety of molecules, such as metals, metabolites and vitamins from the external 
environment, necessary for cell growth and health75. There are two routes of 
endocytosis: phagocytosis (cell eating) and pinocytosis (cell drinking). Briefly, 
phagocytosis refers to the internalisation of particles larger than 0.5 µm, by the 
formation of pseudopod extensions from the cell’s plasma membrane to engulf the 
bound particle76. Pinocytosis refers to the uptake of small particles together with the 
extracellular fluid, and can occur via clathrin-mediated endocytosis, caveolae, or 
macropinocytosis77.  
In order to survey the local microenvironment, macrophages, monocytes and 
immature DCs are adept at taking up antigens from their surroundings78-80. There 
are numerous endocytic receptors on MNPs that mediate endocytosis, including 
mannose receptor (CD206), DEC-205 (CD205), Fc receptors, complement receptors 
and scavenger receptors81-86. Once taken up by MNPs, antigens are sorted into 
different cytoplasmic compartments called endosomes87. Early endosomes are the 
first structures where endocytic vesicles are targeted to88. Here, receptor-ligand 
complexes are dissociated due to the mildly acidic environment (pH 6.0 – 6.8), so 
that receptors can be recycled back onto the cell surface75. Next, the cargo in early 
endosomes can be transported to late endosomes by the migration of vesicles to the 
perinuclear cytoplasm where they fuse with late endosomes, and finally lysosomes 
for degradation. Stimulation via TLRs induces a maturation programme in DCs that 
is characterised by downregulation of phagocytosis and macropinocytosis82,89,90. 
However, there is an initial burst in macropinocytosis prior to downregulation of the 
endocytic machinery91. Also, receptor-mediated endocytosis persists in mature 
DCs92. 
3.2.3.2 Recognition of pathogenic signals induces maturation of DCs 
The concept of innate immune recognition was first theorised by Charles Janeway in 
1989, thus pioneering studies in innate immunity93. The eventual discovery of TLRs 
by Nobel laureates Jules Hoffman and Bruce Beutler and the subsequent elucidation 
of the TLR signalling pathway have been instrumental in our understanding of how 
innate immune cells recognise structurally conserved features of pathogens94,95. This 
adds a layer of sophistication to the innate immune system in the ability to rapidly 
discern if a given antigen that has been endocytosed is harmless or harmful. The 
strategic subcellular compartmentalisation of TLRs also helps to distinguish between 
   11 
self and foreign antigens; TLRs involved in recognition of nucleic acids (TLR3, TLR7, 
TLR8, TLR9) are localised within endo-lysosomal compartments whereas other 
TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6) are on the cell surface. Different 
subsets of human MNPs express distinct repertoires of TLRs, which contribute to 
their functional specialisation96. Further, the tissue specificity of MNPs can also 
determine their TLR expression, as exemplified in DC populations from human blood 
and skin97.  
Upon TLR stimulation, MNPs undergo a cascade of events promoting inflammation 
and their own activation98. Especially for DCs, the maturation programme 
upregulates distinctive genes and signalling pathways, allowing migration to draining 
lymph nodes and efficient activation of T cells47,99. This revolves around the three 
signals required for activation, clonal expansion and differentiation of T cells; signal 1 
comprises antigen-specific interaction between peptide-MHC complex and the TCR, 
signal 2 is delivered by co-stimulatory signals that either promote or inhibit survival of 
T cells, and signal 3 consists of cytokines that can polarise the differentiation of T 
cells into specific subsets of effector T cells100,101. TLR stimulation controls the 
generation of peptide-MHC complexes by regulating the translation and traffic of 
MHC molecules onto the cell surface102,103. Signals through TLRs also result in the 
enhanced expression of co-stimulatory molecules, often used as a measure of DC 
maturation104,105. Co-stimulatory signals include CD80 and CD86 molecules that bind 
to CD28 on T cells thus inducing production of IL-2, which promotes survival of T 
cells. Both CD80 and CD86 can also shut down T cell activation by binding to 
cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which inhibits T cell 
activation. CTLA-4 is upregulated on the cell surface upon T cell activation106. Other 
activating co-stimulatory molecules include CD83 and CD40, whereas OX40 ligand, 
programmed death ligand 1 (PD-L1) and 2 (PD-L2) are inhibitory. Cytokines 
produced by DCs can also promote the differentiation of activated CD4+ T cells into 
various effector Th cells: Th1, Th2, Th17 and Tregs being the most well-
characterised populations107 (Figure 5).  
 
Figure 5. Orchestration of T cell polarisation by MNP-derived cytokine milieu. Recognition of 
PAMPs by MNPs promotes release of specific cytokines that can initiate differentiation of naïve 
CD4+ T cells into subsets with distinct effector programmes.  
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Production of type I interferons (IFN) such as IFN-α and IFN-β, and interleukin (IL) 
12 induces Th1 cells, which promote cellular immunity against intracellular 
pathogens by increasing killing efficacy of macrophages and CTLs, while production 
of IL-4 and transforming growth factor β (TGF-β) promote Th2 responses, supporting 
humoral immunity against extracellular pathogens. Production of IL-6, TGF-β and IL-
23 promote Th17 cells that are important in pathogen clearance at mucosal 
surfaces, including extracellular bacteria and fungi. TGF-β and retinoic acid (RA) 
promotes regulatory T cells (Treg) that are important in the maintenance of tolerance 
against self antigens108. TLR activation of monocytes triggers their differentiation into 
monocyte-derived DCs or monocyte-derived macrophages109. 
3.2.3.3 Antigen processing and presentation to T cells 
DCs excel at antigen processing, as illustrated by their specialised endocytic 
machinery110. Lysosomes contain hydrolytic enzymes that are active in an acidic 
environment (pH 4.5 – 5.0)111. The lysosomal system of DCs has an attenuated 
proteolytic capacity in order to preserve antigenic peptides that can be efficiently 
used for antigen presentation, distinct from macrophages that can rapidly degrade 
internalised proteins to amino acids112. The eventual outcome of antigen 
presentation is determined by whether the antigen is displayed on MHC classes I or 
II, which bind to their cognate T cell receptors (TCRs) and to CD8 or CD4 co-
receptors on T cells respectively (Figure 6).  
 
Figure 6. Antigen presentation via MHC I and MHC II. DCs patrolling the lungs may encounter 
exogenous viral antigen by endocytosing cellular debris containing viruses, or they may acquire 
endogenous viral antigens when they become infected directly. An additional mechanism, cross-
presentation, allows exogenous antigens to be presented on MHC I.     
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Peptides are generated from proteins synthesised (endogenous antigens) or 
acquired (exogenous) by the cell. Endogenous antigens can include both self 
antigens and viral antigens produced as a consequence of viral infection. 
Endogenous antigens are predominantly presented on MHC I, whereas exogenous 
antigens are displayed on MHC II. Classically, activation of CD4+ T cells is optimised 
for elimination of extracellular pathogens by promoting antibody responses, whereas 
activation of CD8+ T cells produces CTLs that can eliminate intracellular 
pathogens14,113. An additional mechanism, called cross-presentation, allows DCs 
that are not directly infected to also activate CTLs by presenting extracellular 
antigens from other infected cells on MHC I molecules to CD8+ T cells, developing 
into effector CTLs114. DCs are described to be superior to monocytes and 
macrophages in being the principal activators of naïve T cells115.  
In immature DCs, lysosomes are enriched in MHC class II molecules, which upon 
maturation can be readily redistributed to peripherally-located vesicles116. Newly 
synthesised MHC II molecules bind a protein termed the invariant chain (Ii), which 
targets the MHC II to endosomal-lysosomal antigen-processing compartments 
containing antigenic peptides. The cleavage of Ii by proteolytic enzymes in these 
compartments results in a small fragment called class II-associated invariant chain 
peptide (CLIP) that remains in the MHC II peptide-binding groove. Upon removal of 
CLIP, an antigenic peptide is loaded and the peptide-MHC II complex traffics to the 
cell surface where they can be presented to CD4+ T cells110.  
MHC I-restricted antigen presentation occurs via a different mechanism, as MHC I 
molecules do not accumulate in the lysosomes of DCs117. Classic MHC I 
presentation occurs when cytosolic proteins undergo proteasomal proteolysis and 
the resulting peptides are translocated into the lumen of the endoplasmic reticulum 
(ER) via the transporter associated with antigen processing (TAP). Here, peptides 
can be loaded on MHC I molecules that are in the ER. For cross-presentation, two 
pathways have been described: vacuolar or cytosolic. The vacuolar pathway is 
independent of proteasomal degradation and TAP activity, instead relying on 
degradation via endosomal or phagosomal proteases such as cathepsin S118,119. 
Peptides are loaded on MHC I within the endosomal compartments. The cytosolic 
pathway requires internalised proteins to be translocated into the cytoplasm and 
targeted to proteasomes, similar to the classical MHC I pathway120. 
3.2.3.4 Division of labour between MNPs 
In human studies, blood MNPs have been the predominant source of cells for 
functional analysis. Here, the functional specialisations of distinct human MNP 
subsets will be discussed.  
CD141+ MDCs are characterised by high expression of TLR3, and respond to 
poly(I:C) by producing pro-inflammatory cytokines TNF, IL-6, IFN-β, CXCL10 and IL-
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12p7058. CD141+ MDCs are also known for their superior capacity to cross-present 
antigens56,58,59,121. Necrotic cell-derived and soluble antigens are cross-presented via 
CLEC9A (also known as DNGR-1)122. In mice, CD8+/CD103+ DCs (homologues of 
CD141+ MDCs) are unique in their cross-presentation capacity with their specialised 
endocytic machinery being well suited for that function (high pH limiting degradation 
and high export to cytosol). However, when investigating lymphoid tissue-resident 
DCs from human tonsils, CD1c+ MDCs and PDCs are also capable of cross-
presentation depending on the source of antigen, especially with TLR stimulation 
and CD4+ T cell help67,68.  
CD1c+ MDCs can respond to a wide range of bacteria- and virus-derived antigens as 
they express high levels of TLRs 1, 2, 4, 5 and 897,123. Upon stimulation, CD1c+ 
MDCs can produce TNF, IL-1β and IL-10123. In addition to their wide TLR repertoire, 
CD1c+ MDCs also express several CD1 glycoproteins, such as CD1a, CD1c and 
CD1d, allowing them to present lipid antigens124. CD1c+ MDCs are extremely 
versatile, as they can induce Th1, Th2 and Th17 polarisation depending on the 
antigen and stimulation55,125,126. When antigens are targeted to early endosomes of 
CD1c+ MDCs, they are equally proficient at cross-presenting antigens as the CD141+ 
MDCs127. This is related to enhanced degradation when antigens are targeted to late 
compartments128. 
PDCs are known for their ability to produce large amounts of type I IFN upon viral 
infection129. They express TLRs 7 and 9 in their endosomal compartments, thus 
allowing them to detect single-stranded RNA and unmethylated CpG sequences in 
DNA molecules respectively, of potentially viral origin130. PDCs can also induce Th1 
or Th2 polarisation131, cross-present antigens119, and induce tolerance by activating 
Tregs132.  
Classical monocytes and intermediate monocytes are superior at phagocytosis 
compared to non-classical monocytes, perhaps related to the expression of CD14, a 
co-receptor for LPS133,134. In response to TLR stimulations, all monocyte subsets 
produce cytokines such as TNF, IL-1β and IL-6 upon TLR stimulation, although there 
are conflicting reports on whether intermediate monocytes134,135 or non-classical 
monocytes136,137 are the most potent responders. All monocyte populations are able 
to stimulate naïve T cells in an allogeneic mixed lymphocyte reaction134. For 
activation of memory T cell responses, antigen presentation by human monocytes is 
impaired in the presence of LPS134,138, due to the presence of IL-10 produced upon 
stimulation of monocytes. Interestingly, both intermediate monocytes and non-
classical monocytes are expanded in blood during infection and inflammation139. 
Inflammatory monocyte-derived cells have been described in synovial and ascites 
fluid sharing gene signatures with in vitro-generated monocyte-derived DCs140. 
Human alveolar macrophages are long-lived, highly phagocytic cells that line the 
airways in close contact with the respiratory epithelium141. Compared to monocytes 
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and DCs, alveolar macrophages are large with a mean diameter of 25 µm and highly 
granular142. They promote tolerance and prevent inflammatory responses to 
harmless antigens by producing immunosuppressive prostaglandins and TGF-β, 
which suppresses T cell activation143,144. 
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4 IMMUNE RESPONSES TO RESPIRATORY VIRUSES 
The respiratory tract is constantly exposed to potential threats in the air. Pathogens 
such as influenza viruses and rhinoviruses are easily transmitted when people cough 
or sneeze, thus causing typical respiratory infections such as the flu or the common 
cold. Another virus that can infect via the airways is hantavirus – when humans 
come in contact with aerosolised virus-contaminated rodent droppings. Both 
influenza virus and hantavirus infections require a robust yet well-regulated immune 
response to eliminate the viruses without causing collateral damage to the delicate 
tissues of the lungs. 
4.1 INFLUENZA A VIRUS 
Influenza viruses causing the flu continue to be a public health concern due to 
annual death and debilitation rates, and the potential to cause severe pandemics. 
According to the World Health Organization (WHO), the seasonal flu can lead to 3–5 
million infections and up to 500 000 deaths every year145. The understanding of 
human influenza immunopathology has been limited, but experimental animal 
models have improved our knowledge of the complex mechanisms surrounding 
influenza infection. 
4.1.1 Brief history of influenza viruses 
Influenza virus was first identified in 1878 as causing an animal disease affecting 
poultry in northern Italy146,147. In 1889, influenza virus entered the human population, 
resulting in the first recorded pandemic (Table 1), killing approximately 1 million 
people worldwide148. In 1918, an even more devastating pandemic flu ensued. 
Despite its name, the Spanish flu resulted in massive deaths not only in Spain, but 
also worldwide. Reports of the flu was censored at that time to maintain morale 
during the war149. Most deaths occurred among youths who succumbed to bacterial 
pneumonia, a secondary infection after the flu. Nevertheless, some patients also 
died soon after the onset of symptoms with massive haemorrhaging or fluid in the 
lungs. Based on autopsies performed on Spanish flu victims, the primary cause of 
death was pneumonia and respiratory failure150. 
Name of pandemic Date Deaths Subtype involved 
Russian Flu 1889–1892 1 million H3N8 or H2N2 
Spanish Flu 1918–1920 20–100 million H1N1 
Asian Flu 1957–1958 1–1.5 million H2N2 
Hong Kong Flu 1968–1969 0.75–1 million H3N2 
Swine Flu 2009–2010 18 000 – 284 500 H1N1/09 
 
Pandemics stem from the transmission of novel viral strains from animal reservoirs 
into the human population. This occurs by reassortment of viral genome from two 
Table 1. Known influenza pandemics throughout history.   
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distinct strains of influenza, termed “antigenic shift”. The first pandemic of the 21st 
century happened in 2009 when an H1N1 virus of swine origin entered the human 
population151. Transmission of avian strains occurs sporadically, albeit in a dead end 
fashion due to the limited ability of the virus to be transmitted between humans152,153. 
The highly pathogenic H7N7 affecting the Netherlands in 2003 or the H7N9 in China 
in 2013 were consequences of exposure to infected poultry on farms. While 
antigenic shifts occur occasionally resulting in pandemics, small changes in the 
genes of influenza viruses arise continuously. These changes, termed “antigenic 
drift”, accumulate over time as a result of viral variants escaping immune pressure. 
This necessitates the annual update of influenza vaccines, in order to review the 
composition of vaccines to keep up with evolving viruses145.  
4.1.2 Clinical signs and symptoms 
Influenza virus infection may lead to three syndromes: a respiratory illness, a primary 
viral pneumonia, or a secondary bacterial pneumonia154 (Figure 7). Uncomplicated 
cases of influenza are characterised by a sudden onset of respiratory illness, 
including fever, headache, general discomfort, muscle ache, sore throat and runny 
nose155. The illness resolves after 3-7 days for most people, with cough persisting for 
more than 2 weeks155. In severe cases, primary viral pneumonia is common, also 
frequently a cause of death156. Secondary bacterial pneumonia is estimated to occur 
in up to 30% of fatal cases157, with respiratory failure being the cause of death.  
 
 
4.1.3 Genome organization, structure and replication 
Influenza viruses belong to the Orthomyxoviridae family of negative-sense single-
stranded RNA viruses, consisting of eight genome segments (Figure 8). Influenza 
viruses are classified into three types: A, B and C. Influenza A and B viruses are 
responsible for causing seasonal epidemics, whereas influenza C infections cause a 
mild respiratory illness.  
Figure 7. Model of influenza virus syndromes. After 1-2 days of incubation, three syndromes of 
varying severity may occur. Viral pneumonia has a rapid onset of 1 day post infection. 
Uncomplicated illness peaks after 3-5 days and subsides within a week. However, if a secondary 
bacterial infection occurs, recovery is impeded and symptoms progressively worsen.  
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The focus of this thesis is on IAV, the most abundant and pathogenic influenza virus 
to infect humans. The eight RNA segments encode for up to 16 proteins; multiple 
proteins may be expressed due to alternative splicing of the same RNA fragment, 
but not all influenza viruses express all 16 proteins158 (Table 2).  
Gene segment Protein Function 
1 Polymerase PB2 Component of RNA-dependent RNA polymerase 
2 Polymerase PB1 
N40 
PB1-F2 
Component of RNA-dependent RNA polymerase 
Unknown function 
Pro-apoptotic 




Component of RNA-dependent RNA polymerase 
Represses cellular gene expression 
Unknown function 
Unknown function 
4 Haemagglutinin HA Binds sialic acids on host cell receptors 
5 Nucleoprotein NP Binds viral RNA and other proteins, nuclear import 
6 Neuraminidase NA Cleaves off sialic acids from cell surfaces 
7 Matrix protein M1 
Matrix protein M2 
Matrix protein M42 
Matrix protein 
Ion channel protein 
Ion channel protein 
8 Non-structural protein NS1 
Non-structural protein NS2 
Antiviral response antagonist 
Nuclear export protein 
 
Each virion is roughly spherical, but sometimes filamentous, and measures 
approximately 80-120 nm in diameter159. The viral envelope is made of a lipid 
membrane embedded with glycoproteins haemagglutinin (HA) and neuraminidase 
(NA), and M2 proteins that form ion channels across the membrane. M1 proteins 
form a shell underneath the lipid membrane. Proteins PB1, PB2 and PA form the 
RNA-dependent RNA polymerase. Each viral RNA is tightly bound around many 
copies of nucleoprotein (NP). The viral RNAs, NP molecules, and RNA polymerase 
together form the viral ribonucleoprotein (vRNP).  
Figure 8. Influenza structure, genes and proteins.  Two surface glycoproteins, haemagglutinin 
(HA) and neuraminidase (NA), and an ion channel M2 are embedded in the viral envelope, derived 
from the host cell plasma membrane. Three polymerase proteins (PB1, PB2, PA) are associated 
with viral RNA bound to nucleoprotein (NP), packaged inside the virion. Matrix protein M1 forms a 
shell underneath the viral envelope. 
Table 2. Influenza A virus RNA segments and proteins encoded. 
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Infection is initiated when IAV particles enter and bind to cells in the upper 
respiratory tract epithelium. In humans, HA recognises host cell receptors, both 
glycoproteins and glycolipids, containing sialyloligosaccharides terminated by N-
acetyl sialic acid linked to galactose with an α2,6 linkage, as opposed to HA on avian 
viruses which prefer sialic acids with α2,3 linkage160. Epithelial cells in the human 
trachea contain these sialic acid residues161. Nevertheless, infection with avian flu in 
humans occur as there are cells in the lower respiratory tract in humans that contain 
α2,3-linked sialic acids162. 
Extensive studies combining microscopy and biochemical methods have elucidated 
the influenza virus life cycle, summarised in Figure 9158,163,164. After the virus is 
attached via binding of HA to sialic acid, virus particles are internalised via 
endocytosis165-168. Lakadamyali et al. described by visualising individual viruses in 
real-time in living cells, that influenza progresses to the nucleus in three distinct 
stages169. Firstly, the endocytic vesicles are transported to early endosomes via an 
actin-dependent manner. Secondly, virus-containing early endosomes are rapidly 
transported towards the perinuclear region via dynein-mediated movement on 
microtubules. Here, acidification of endosomes takes place. Finally, the acidic 
environment (pH ~5) triggers conformational changes of HA resulting in fusion of 
viral and host cell membranes170-172. The ion channel M2 further acidifies the internal 
compartment of the virus, allowing vRNPs to dissociate from M1. The uncoated 
vRNPs are then released into the cytoplasm, and enter the nucleus of the host cell 
via nuclear localisation signals on NP173. 
 
 
Influenza viruses are one of the few RNA viruses to undergo replication in the 
nucleus174. The negative-sense viral RNA is transcribed to positive-sense RNA for 
Figure 9. Influenza virus life cycle and replication. Upon binding to sialic acid residues on host 
cells, a virion is endocytosed and targeted to early endosomes, followed by late endosomes where 
the low pH allows fusion and penetration of the viral genome into the cytoplasm. vRNPs are 
transported into the nucleus where the negative-sense RNA acts as a template for mRNA to be 
translated to viral proteins in the cytoplasm, or cRNA for synthesis of new viral genome. Assembly 
takes place at the plasma membrane where new virions eventually bud off. 
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two purposes: viral messenger RNA (mRNA) for protein synthesis, and viral 
complementary RNA (cRNA) for synthesis of more negative-sense RNA as the 
genomic content of new virions175. Viral mRNA are capped on the 5’ end from the 
host’s RNA is a process called cap snatching. Capped viral mRNA are exported to 
the cytoplasm for viral protein synthesis using the host cell’s ribosomal machinery. 
Newly synthesised viral proteins such an NP and the RNA polymerase complex get 
imported into the nucleus where they associate with the newly synthesised vRNA.  
Prior to viral assembly, HA proteins (HA0) need to undergo cleavage to be 
processed into two subunits (HA1 and HA2). This is a necessary step as HA2 
contains the fusion peptide required for entry into the next cell. The protease 
mediating cleavage in humans is thought to be tryptase produced by club cells 
(previously called Clara cells) residing in the respiratory tract176. This limits the 
spread of influenza infection in humans as uncleaved HA remain non-infectious. 
Nevertheless, HA of avian strains may be cleaved by other proteases, resulting in a 
more extensive pattern of infection, with H5N1 being detected in multiple organs177. 
Finally, the individual components assemble at specialised areas of the plasma 
membrane, rich in lipid rafts, with M1 being central to this interaction. Viral budding 
occurs via the action of NA, a sialidase, that can remove sialic acids from the surface 
of host cells175. This is so that newly released virus particles do not immediately re-
bind to their receptors, but instead are released into the extracellular space where 
they may infect a neighbouring cell. This has been exploited to the development of 
NA inhibitors as antiviral drugs (e.g. sialic acid analogues, Zanamivir and 
Oseltamivir). 
4.1.4 Immune responses to IAV 
In this thesis, key studies from murine studies are briefly discussed, with a greater 
focus on the existing literature on influenza infection of humans. Both the innate and 
adaptive arms of the immune system play important roles in viral control and 
eventual clearance178,179. Coincidentally, an exaggerated innate immune response 
may also contribute to disease, including acute respiratory distress syndrome 
(ARDS), suggesting the importance of a tightly regulated and well-orchestrated 
immune response to the infection. 
Upon penetration of the mucosal layer, the first innate barrier against infection, IAV 
can enter a variety of cells in the respiratory tract, including ciliated epithelial cells, 
type I and type II alveolar cells, and immune cells180,181. Equipped with virus-sensing 
receptors, respiratory epithelial cells respond by secreting various cytokines and 
chemokines such as type I IFNs, IL-6, TNF and IL-8 to limit the initial viral replication, 
and to trigger the recruitment of other immune cells182. Although pro-inflammatory 
cytokines are necessary for initiation of immunity against influenza virus, an 
aggressive cytokine storm may also exacerbate the disease by causing injury to the 
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delicate tissues of the lungs. In the Spanish flu pandemic of 1918, the inflammatory 
environment due to increased recruitment of leukocytes may have contributed to 
increased morbidity183. Local and systemic increase in cytokine levels during 
infection has been reported in influenza-infected patients and also in participants of 
human challenge studies184-186. In the 2009 H1N1 pandemic, a dysregulated 
cytokine response correlated to more severe disease187. Interestingly, although IAV 
infection eventually leads to cell death due to apoptosis/necrosis or clearance by 
effector immune cells, club cells can survive IAV infection and maintain heightened 
levels of interferon stimulated genes (ISGs) for a prolonged time after virus has been 
cleared, thus driving non-specific immunity against subsequent viral infections188,189. 
The innate response limits viral replication while the adaptive response is 
developing. This is initiated by tissue-resident alveolar macrophages and DCs 
residing in the respiratory tract that patrol and probe the surroundings for presence 
of microbial components. Upon release of inflammatory mediators, more neutrophils 
and monocytes infiltrate into the site of infection. As highly phagocytic cells, they are 
important for clearance of infected and apoptotic cells190,191.  
In influenza-infected mice, both myeloid DC subsets and PDCs with an activated 
phenotype accumulate in the trachea and lung interstitial tissue192-194. Monocyte-
derived DCs also infiltrate the lungs195,196. DCs secrete pro-inflammatory cytokines 
and chemokines and migrate to draining lymph nodes to induce adaptive immune 
responses192-194,197,198. Distinct subsets of DCs differ in their capacities to induce 
CD8+ cytotoxic T lymphocytes (CTLs), with CD103+ MDCs (cDC1) identified as the 
key subset presenting antigen to drive the proliferation of lung-homing flu-specific 
CD8+ T cells197,199,200. Confirming the important role of DCs in viral control, depletion 
of DCs in mice before challenge with influenza resulted in higher viral load in the 
lungs and increased mortality192,194,201. Similarly in humans, DCs have been reported 
to accumulate in the nasal mucosa, whereas numbers in peripheral blood are 
reduced202-204. In vitro studies of human DC subsets suggest that infection with 
influenza viruses induce upregulation of MHC molecules, co-stimulatory molecules 
and chemokine receptors205-210. A potential consequence of viral infection of DCs is 
impaired function, as blood CD1c+ DCs (cDC2) infected with IAV resulted in poorer 
expansion of flu-specific CD8+ T cells210. 
In mouse models, depletion of alveolar macrophages has shown contrasting results, 
possibly dependent on the virus strain and dose used. Depletion of alveolar 
macrophages did not affect severity of disease upon lethal PR8 infection, but caused 
uncontrolled viral titres when challenged with H1N1 pandemic isolate211. In humans, 
IAV infection of alveolar macrophages does not cause excessive TNF production212.  
In mice, CCR2-dependent recruitment of monocytes to the lungs is critical to both 
the innate immune response against influenza by production of pro-inflammatory 
cytokines, and also by enhancing influenza-specific T cell responses213,214. In 
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humans, increased numbers of monocytes are found in the nasal mucosa203,204,215 
and in peripheral blood of influenza-infected patients203,204,215-217. 
Neutrophils have been shown to be important for controlling viral replication in 
mouse models218. Depletion of neutrophils resulted in increased viral titres in the 
lungs219. In humans, addition of activated neutrophils to a culture of bronchoalveolar 
lavage (BAL) cells in vitro improves viral clearance220. In contrast, in vitro infection of 
human neutrophils induces apoptosis221. The specific role of neutrophils during 
influenza infection in humans in vivo remains unclear. 
NK cells accumulate in the lungs of mice challenged with IAV, with an activated 
phenotype that can lyse infected cells via the action of granzyme B and perforin222-
224. To confirm the importance of NK cells, depletion of NK cells resulted in delayed 
viral clearance222. In influenza-infected patients, infection resulted in a transient 
deficiency of circulating NK cells225-228. Although this may reflect recruitment of NK 
cells to the site of infection, investigations in fatal cases of IAV infections revealed 
low numbers or absence of NK cells in the lungs228,229. 
The adaptive immune response, both humoral and cellular immunity, act at different 
time points to limit disease caused by an acute respiratory viral infection. Cellular 
immunity via the action of CTLs is important for eliminating virus-infected cells thus 
reducing disease severity. Humoral immunity through B cells and antibodies 
represent the major mechanism for prevention of re-infection. The induction of 
durable and effective immunological memory ensures protection from re-infections.  
Flu-specific antibodies have long been used as a correlate of protection. Since the 
1960s, experimental human challenges have demonstrated that lasting immunity 
correlated with antibody levels230. Priming of naïve B cells is thought to occur when 
DCs that have acquired viral antigens from the respiratory tract transport them to 
lymphoid tissues; draining lymph nodes or nasal/bronchial-associated lymphoid 
tissue231,232. Short-lived plasmablasts are formed at this stage, that can go on to 
become antibody-producing long-lived plasma cells233. In parallel, memory B cells 
are also formed that can rapidly develop into plasmablasts in subsequent re-
infections. As influenza infections are primarily restricted to the respiratory tract, 
mucosal IgA plays an important role in preventing infection. IgA-secreting B cells are 
preferentially generated in bronchial-associated lymphoid tissues234. IgA knockout 
mice are poorly protected against influenza235. Human studies have mainly focused 
on B cell responses in the peripheral blood. During natural infection, IAV-specific 
plasmablasts can be readily detected 7-10 days after symptom onset236,237. 
Formation of bronchial-associated lymphoid tissue has been difficult to demonstrate 
in humans238. Nevertheless, protective humoral responses continue to be a 
benchmark for development of vaccine-induced immunity.  
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Primary T cell responses are also generated in lymphoid organs, upon delivery of 
viral antigens from the lungs by DCs. Both CD4+ and CD8+ T cells play important 
roles in adaptive immune responses to influenza239. CD4+ T cells have a wide 
repertoire of functions, providing help for both CD8+ T cells and also B cells. In 
human influenza infection models, pre-existing memory CD4+ T cells provided 
protection against influenza challenge240. Influenza is typically associated with Th1 
responses, involving production of IFN-γ, TNF and IL-2241. Importantly, memory 
CD4+ T cells remain in lung tissue to provide rapid and optimal responses to 
secondary influenza infections. In the lymph nodes, DCs imprint CD4+ T cells with 
chemokine receptors and integrins that allows them to home to the lung tissue and 
remain there107. This was shown in mice to be mediated by expression of CCR4 on 
T cells, driven by lung DCs242. CCR4 binds to CCL5 (also known as RANTES) 
expressed by epithelial cells in the lungs during infection243.  
Viral clearance during influenza infection requires the activation of CTLs244. 
Furthermore, generating IAV-specific CD8+ T cells is an attractive vaccine strategy, 
as they are predominantly directed towards conserved internal proteins, hence 
providing broader cross-reactive protection against distinct strains of IAV245. As 
mentioned earlier, IAV-specific T cell responses are initiated in the draining lymph 
nodes. However, recent advances in mouse models have indicated that upon arrival 
to the IAV-infected lungs, the local lung environments can shape the differentiation 
of T cells into effector cells246. CTLs downregulate their ability to secrete IFN-γ in the 
lungs, to avoid causing collateral damage247. They can also produce IL-10, which 
functions to inhibit excessive pulmonary inflammation248. Lung DCs can also provide 
additional survival and proliferative signals by interacting with CD8+ T cells249,250. 
Indeed, depletion of lung MNPs reduced CTL proliferation192. In humans, the 
importance of CD8+ T cells in protecting against influenza have been confirmed in an 
extensive study involving 342 participants with natural infection251. The IAV-specific 
CD8+ T cell responses are long-lived252. Further, IAV-specific memory CD8+ T cells 
are more frequent in the lungs than in blood or spleen, with a resident memory T cell 
phenotype (expressing CD69 and CD103)253-255.  
4.2 HANTAVIRUS 
Hantaviruses pathogenic to humans are rodent borne, but do not cause 
pathogenesis in their natural hosts256. Transmission to humans via aerosolised 
excreta may lead to HFRS or HPS depending on the viral species257.  As an 
emerging infectious disease, hantavirus infections represent a threat to public health 
worldwide. The annual incidence of reported hantavirus infections varies depending 
on geographical location: approximately 250 cases in the Americas, 3000 in the 
Nordic countries and almost 40 000 in China258. 
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4.2.1 Brief history of hantaviruses 
An important outbreak of hantavirus occurred during the Korean war in 1950s, when 
more than 3000 United Nation soldiers presented with a febrile illness characterised 
by acute renal failure259,260. Prior to that, similar symptoms had been reported in 
China in 960 AD, among French troops in 1915, in Sweden in 1930s, and in East 
Siberia in 1940s, without an understanding of the causative agents. Eventually, the 
discoveries of Hantaan virus (HTNV) in Asia and Puumala virus (PUUV) in Europe 
shed light on the aetiology of HFRS. In 1993, a mysterious outbreak of a pulmonary 
illness occurred in “The Four Corners” of United States that led to the discovery of 
Sin Nombre virus (SNV), and other hantaviruses endemic to the Americas. Infections 
caused by SNV and other American hantaviruses were categorised as HPS due to 
severe pulmonary failure associated with the virus infection261. 
4.2.2 Clinical syndromes 
Viruses from Eurasia can cause HFRS whereas viruses from the Americas may lead 
to HPS. However, mounting evidence suggests a more diffuse pattern of symptoms, 
as patients infected with PUUV may also present with pulmonary symptoms to the 
extent of fatality due to respiratory failure262-264. A common hallmark of both 
syndromes is increased vascular leakage leading to low blood pressure, dilation of 
blood vessels and acute loss of thrombocytes. In the case of HFRS, vascular beds in 
the kidneys are most affected, whereas in HPS, pulmonary capillaries are 
compromised265. 
Patients with HFRS experience an abrupt fever followed by headache, nausea, 
vomiting and abdominal pain266. Kidney problems begin to manifest with back pain 
and tenderness, including oliguria or low urine output and excessive protein or blood 
in urine. Elevated levels of creatinine in blood are indicative of an acute kidney 
failure. In the second week of illness, patients transition to polyuria or excessive 
urine output as the kidneys improve in function. HFRS patients typically recover after 
two weeks. Most fatalities associated with HFRS occur during the hypotensive shock 
stage267,268, with a case fatality rate of 0.1-10%257.  
The clinical manifestations of HPS range from mild oxygen deficiency in the blood, 
fluid accumulation in the lungs, to respiratory failure269. Patients typically exhibit 
respiratory manifestations such as coughing and shortness of breath, with up to 60% 
of cases requiring mechanical ventilation270. Other symptoms are comparable to 
HFRS, such as fever, low platelet counts, increased creatinine levels and protein in 
urine271-274. Rapid progression of HPS may lead to death within hours after the onset 
of cardiopulmonary phase275, with up to 40% case fatality rate257. 
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4.2.3 Genome organization, structure and replication 
Hantaviruses belong to the Bunyaviridae family of negative-sense single-stranded 
enveloped RNA viruses, with three genome segments (Figure 10). Each segment, 
called small, medium and large contains an open reading frame encoding the 
nucleocapsid (N) protein, the glycoprotein precursor that matures into Gn and Gc, 
and the RNA-dependent RNA polymerase (RdRp), respectively. The morphology 
and structure of hantaviruses have been elucidated by electron microscopy276-278. 
Hantaviruses are described as round particles of 120-160 nm in diameter278. Each 
virion comprises of a lipid envelope covered with spikes (made up of Gc and Gn) 
that protrude out of the membrane. Within the virion, the viral RNA segments are 
encapsidated by N proteins. Critical to hantavirus transmission, the virions are 
stable at room temperature for 10 days and even longer at 4°C to -20°C279,280.  
 
Hantaviruses replicate in the vascular endothelium281. As such, endothelial cell 
lines have been relied on for in vitro studies investigating the molecular 
mechanisms of viral entry and replication, summarised in Figure 11265. Host cell 
integrins, that promote adhesion of cells to the adhesion matrix, mediate hantavirus 
entry into cells, but this has not yet been confirmed in vivo. Interestingly, 
pathogenic and non-pathogenic strains of hantaviruses utilise distinct integrins for 
entry, αVβ3 and α5β1 respectively282. After binding a receptor on the surface of a 
host cell, the hantavirus is taken up by the cell by various methods of 
endocytosis257,283. Similar to influenza viruses, hantaviruses are trafficked to early 
and late endosomes where the low pH triggers a change in the conformation of the 
Gc glycoprotein, allowing binding of the Gc fusion loop to the endosomal 
membrane, eventually leading to fusion of viral and cellular membranes257. The 
viral genome is then released into the cytoplasm where viral replication can begin. 
Transcription of viral RNA begins at the ER-Golgi intermediate compartment 
(ERGIC). Nascent virions assemble and bud into the cis-Golgi where they are 
transported to the plasma membrane for release via exocytosis.   
Figure 10. Hantavirus structure, genes and proteins. Spike complexes comprising two surface 
glycoproteins, Gn and Gc, are embedded in the viral envelope, derived from the host cell plasma 
membrane. Each RNA polymerase is associated with viral RNA bound to nucleocapsid proteins, 
packaged inside the virion.  




4.2.4 Immune responses to hantaviruses 
The immune response to hantavirus infection is of relevance to study as the 
pathogenesis of hantavirus has been suggested to be immune mediated284. The 
exact sequence of events beginning from inhalation of hantaviruses in the lungs to 
systemic viral dissemination has not yet been elucidated in vivo. Nevertheless, ex 
vivo assessment of viral RNA or protein in patients, combined with in vitro studies 
indicate that in the lungs, hantavirus may result in infection of lung endothelial cells, 
epithelial cells or immune cells present in the lungs such as alveolar macrophages or 
DCs263,285-288. Recognition of vRNA by PRRs triggers a cascade of signalling 
pathways leading to production of type I IFNs and other pro-inflammatory 
cytokines289. The precise PRR responsible for recognition of genomic RNA has yet 
to be identified. Hantaviruses are relatively poor inducers of type I IFNs, but the ISG 
MxA has been detected in endothelial cells following hantavirus infection, 
colocalising with the hantavirus N protein290-292. These cytokines are important in 
limiting viral spread, via direct effects of type I IFNs but also the recruitment of other 
innate immune cells such as NK cells to the site of infection263,293,294. Monocytes, 
macrophages and lymphocytes may also respond by producing pro-inflammatory 
cytokines such as TNF, IL-1 and IL-6. Indeed, high levels of cytokines have been 
found in the plasma, urine and tissues of hantavirus patients295-298. Human blood and 
monocyte-derived DCs from healthy volunteers are also susceptible to hantavirus 
infection in vitro299. After replication in endothelial cells, virions are released into 
peripheral blood circulation, and hantavirus RNA can be detected in patients for 
diagnosis300,301. Hantaviruses can be disseminated to other organs, including the 
kidneys and bone marrow302,303.  
Figure 11. Hantavirus life cycle and replication.  Upon binding to integrins on host cells, 
incoming virions are endocytosed and targetted to early endosomes, followed by late endosomes 
where the low pH allows fusion and penetration of the viral genome into the cytoplasm. 
Transcription of viral RNA begins at ERGIC. New virions assembly and bud into the cis-Golgi 
where they are targeted to the plasma membranes via recycling endosomes.  
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Activation of the adaptive immune system can be categorised by humoral and 
cellular immune responses to hantavirus. Elevated levels of total and virus-specific 
IgA, IgE, IgM and IgG have been reported in patients with acute HFRS304. The virus-
specific antibodies persist in sera of patients, providing long-lasting immunity against 
hantavirus infections305,306. Neutralising antibodies recognise epitopes on the 
glycoproteins Gc and Gn, with a high level of cross-reactivity towards different 
hantaviruses304. A significant association between low virus-specific IgG responses 
and more severe disease indicates an important role of humoral immune responses 
in managing hantavirus pathogenesis307. In contrast, high numbers of virus-specific 
CTLs appear to be correlated with disease severity. CD8+ T cells play a central role 
in the cellular immune response against hantavirus. High numbers of CD8+ T cells in 
blood and BAL have been associated with severe HPS and HFRS requiring 
mechanical ventilation or oxygen treatment308,309. In the lungs of patients who died 
from HPS and HFRS, increased numbers of CD8+ T cells producing TNF, IL-2 and 
IFN-γ were detected310. Surprisingly, hantavirus-infected endothelial cells are 
protected from CTL-mediated induction of apoptosis311. Further investigations are 
required to understand why CTLs remain activated in hantavirus-infected patients, 
despite an impaired ability to eliminate infected cells.  
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5 MATERIALS AND METHODS 
A brief description of the central methods and underlying principles are outlined in 
this chapter. Detailed information of materials and methods can be obtained in the 
original papers (I–IV). 
5.1 BRONCHOSCOPY 
In papers III and IV, bronchoscopies were performed to obtain lung specimens from 
healthy volunteers and hantavirus-infected HFRS patients who provided written and 
oral consent. It is a procedure done by a team of trained nurses and a respiratory 
physician. Participants were first treated with oral and intravenous anaesthetics 
approximately 30 minutes before the bronchoscopy. A flexible bronchoscope was 
inserted into the airways through the mouth, allowing visualisation of the inside of the 
airways. Topical anaesthesia was sprayed onto the distal trachea and bronchi via 
the bronchoscope. Using fenestrated forceps, endobronchial biopsies (EBB) were 
taken from the main carina and the main bronchial divisions. From the contralateral 
side, bronchial wash (BW) of 2 x 20 mL saline solution, followed by BAL of 3 x 60 mL 
were taken to sample the airways. 
5.2 PROCESSING OF BLOOD, BW, BAL AND EBB 
For papers I and II, buffy coats, the fraction of whole blood after density 
centrifugation that is enriched in leukocytes, were used from healthy blood donors at 
Karolinska University Hospital. Buffy coats were diluted in PBS at a ratio of 1:1, 
layered over a Ficoll gradient, and centrifuged at 1000 g for 25 minutes with no 
brake to obtain peripheral blood mononuclear cells (PBMCs). For studies III and IV, 
peripheral blood was collected in CPT tubes (BD) already containing Ficoll solution, 
and centrifuged according to manufacturer’s instructions. Ficoll is a synthetic, high 
molecular weight polymer of sucrose and epichlorohydrin312. Differential migration of 
cells during centrifugation through the density gradient results in the formation of 
layers: red blood cells aggregate and settle on the bottom, followed by denser 
granulocytes that can migrate through the Ficoll gradient, the Ficoll layer, an 
interface of PBMCs and finally the plasma layer. PBMCs consisting of monocytes, 
lymphocytes and platelets are not dense enough to migrate through the Ficoll layer.  
In papers III, BW and BAL were kept on ice immediately after collection, and 
centrifuged at 400 g  for 15 minutes at 4°C to separate the fluid from the cells. Intact 
biopsy specimens were washed and incubated in 1,4-Dithiothreitol (DTT) to remove 
mucous and enzymatically digested with collagenase and DNase to obtain single 
cells for flow cytometry. In parallel, several EBB were fixed in acetone and 
embedded in glycol methylacrylate (GMA) resin for tissue sectioning and 
immunohistochemical analysis. To assess whether the enzymatic digestion might 
cleave off, alter or interfere with antibody binding, PBMCs expressing similar 
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markers were treated with the digestive enzymes and stained with the same 
antibody panel used for flow cytometry. Additionally, tissue sections were also 
stained with specific antibodies by immunohistochemistry to confirm that epitopes 
were not lost upon enzymatic digestion.  
All single cells from peripheral blood, BW, BAL and digested EBB were counted 
manually using Trypan Blue exclusion to measure viability. Cells were subsequently 
stained with antibodies for flow cytometric analysis. 
5.3 ISOLATION AND GENERATION OF DCs 
In papers I and II, MDDCs were generated by culturing enriched monocytes, 
obtained by RosetteSep monocyte enrichment (StemCell Technologies), at a 
concentration of 0.5 x 106 cells per mL of R10, RPMI-1640 cell culture medium 
containing 10% fetal bovine serum (FBS), containing recombinant human GM-CSF 
(40 ng/mL) and IL-4 (40 ng/mL) (both Peprotech) for six days.  
In paper II, blood CD1c+ MDC and PDCs were isolated by magnetic isolation using 
anti-CD1c (BDCA-1) or anti-CD304 (BDCA-4) antibodies conjugated to MACS 
microbeads, (Miltenyi Biotec) beginning from enriched monocytes and PBMCs 
respectively. CD1c+ MDCs were cultured in R10 with 2 ng/ml GM-CSF whereas 
PDCs were cultured in R10 with 1 ng/ml IL-3.  
5.4 STIMULATION AND IN VITRO INFECTION OF DCs 
In paper I, MDDCs were adhered on Alcian-blue coated coverslips and exposed to 
IAV/X31 (derived from influenza A/Aichi/2/68; H3N2) at a multiplicity of infection 
(MOI) of 25 (as assessed by MDCK plaque assays) for 60 minutes at 4°C to allow 
virus particles to bind to the surface of cells. Infection was allowed to proceed at 
37°C with cells being washed and fixed between 0-30 minutes, to capture the early 
events of viral entry. The pulse at 4°C ensures a more synchronised process of viral 
entry by eliminating the variation in how long it takes for each virus particle to settle 
on the cells by gravity. 
In paper II, MDDCs and CD1c+ MDCs were stimulated overnight with a panel of 
purified TLR ligands: Polyinosinic:polycytidylic acid (poly(I:C)), lipopolysaccharide 
(LPS), and 3M019 (7/8L). poly(I:C) resembles double stranded RNA and binds TLR3 
to simulate a viral infection. LPS is an endotoxin found in the outer membrane of 
Gram-negative bacteria. 3M019 is an imidazoquinoline compound, a synthetic 
molecule resembling a nucleic acid base that binds to TLR7/8. Supernatants and cell 
lysates were harvested after the overnight stimulation for RNA and protein analyses. 
In parallel, stimulated cells were exposed to IAV/X31 at an MOI of 0.6 for 24 hours 
and cells were then analysed by flow cytometry.  
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In paper III, bulk PBMCs and BAL cells were stimulated with the TLR ligands for 3 
hours with brefeldin A (BFA) added after 30 minutes to prevent release of cytokines, 
so that production of TNF can be assessed by intracellular staining using flow 
cytometry. BFA is an antibiotic produced by fungal organisms that works by inhibiting 
protein transport from the ER to the Golgi apparatus, resulting in accumulation of 
newly produced proteins in the ER.   
5.5 FLOW CYTOMETRY 
Different flow cytometers have been used in this thesis: BD FACSCanto II in paper I, 
BD FACSCalibur in paper II, BD LSRII and BD LSRFortessa in papers III and IV. 
Additionally, cells were sorted on a MoFlo XDP (Beckman Coulter) for RNA analysis 
in paper II.  
Flow cytometry is a technology combining fluidics, optics and electronics to allow 
single cells labelled with fluorescence-conjugated antibodies to flow in a stream of 
fluid through a beam of light313. The illuminated particles emit light at specific 
wavelengths that can be detected by the electronics of the instrument, thus 
measuring relative fluorescence intensities. Additionally, relative size and 
granularity/internal complexity can also be measured.  
Cells were stained with a panel of antibodies conjugated with different fluorochromes 
targeting different cell surface receptors that may be expressed by specific cell 
types. For intracellular staining, cells were first fixed with paraformaldehyde followed 
by permeabilisation with saponin, and staining with antibodies against intracellular 
proteins such as transcription factors or cytokines. Paraformaldehyde forms intra-
molecular cross-links to preserve the morphology of cells prior to formation of holes 
in the membrane to allow the antibodies to gain access to the intracellular 
proteins314. Saponin forms holes by selectively removing cholesterol in the plasma 
membrane315. 
5.6 MICROSCOPY 
Similar to flow cytometry, the core principle behind fluorescence microscopy is 
immunofluorescence; cells were stained with fluorescence-conjugated antibodies 
binding to specific host cell proteins or viral proteins. The microscope then 
illuminates the specimens at specific wavelengths to visualise multiple proteins. 
Unlike flow cytometry, microscopy provides a greater degree of subcellular spatial 
understanding. Confocal microscopy is advantageous over regular epifluorescence 
microscopy with the addition of a pinhole to eliminate out-of-focus light316. This 
enables the collection of multiple slices of images at different depths so that there 
can be a 3 dimensional (3D) reconstruction of the entire volume of a cell. Stimulated 
Emission Depletion (STED) microscopy further enhances the resolution of images by 
adding a second laser of lower energy overlapping the excitation spot in a doughnut-
shaped beam317. This additional stimulation sends excited fluorophores back to their 
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ground state; in a non-fluorescent state. This improves the resolution of images by 
distinguishing two close molecules within the range of 30-80 nm apart, as compared 
to the 250 nm resolution of a regular confocal microscope. 
In paper I, confocal images were acquired on a Zeiss LSM700 using a 63x objective 
and STED images were acquired on a Leica SP8 STED 3X platform using a 100x 
white light, with a numerical aperture 1.4 oil immersion objective.  
In papers III and IV, sections of EBB embedded in GMA were stained with 
antibodies against specific proteins, but instead of a fluorescence molecule, a 
biotinylated secondary antibody was added, allowing visualisation by adding of a 
strepatividin-peroxidase complex that can be imaged by a light microscope. For 
cellular analysis, positively-stained, nucleated cells were counted within the bronchial 
submucosa and intact epithelium, excluding areas of smooth muscle, glands, large 
blood vessels and mismatched or damaged tissue. 
5.7 RNA AND PROTEIN ANALYSES 
Proteins secreted by cells that were harvested in supernatants were analysed using 
commercially available ELISAs to detect pro-inflammatory cytokines such as TNF, 
IL-6 and IFN-α for papers II and IV. Additionally, a type I IFN bioassay was 
developed in-house to detect small but biologically active levels of type I IFNs in 
paper II. Briefly, type I IFNs were detected indirectly by measuring the extent to 
which adding supernatants potentially containing type I IFNs can rescue a cell line 
from cell death upon challenge with Semliki Forest Virus (SFV).  
Proteins produced by cells were harvested in cell lysates and analysed by Western 
blots in paper II. Proteins were first separated by molecular weight using sodium 
dodecyl sulphate-polyacrylamide (SDS-PAGE) and then transferred to a 
polyvinylidene fluoride (PVDF) membrane. ISGs including ISG15 and MxA were 
detected by standard immunoblotting using peroxidase-conjugated secondary 
antibodies.  
In paper II, total RNA from sorted cells was extracted using Qiagen RNeasy kit 
according to manufacturer’s instructions. cDNA was synthesised using a cDNA 
reverse transcription kit. 48 TaqMan gene expression assays were pre-configured on 
a microfluidic card with 384 wells. Quantitative real-time polymerase chain reaction 
(qRT-PCR) was performed on a QuantStudio 7 flex system and gene quantities 
were measured relative to an endogenous housekeeping gene.   
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6 RESULTS AND DISCUSSION 
This thesis was initially built upon a key finding by Smed Sörensen et al. describing 
how human blood CD1c+ MDCs are susceptible to IAV infection, and that infected 
DCs have an impaired capacity to present IAV antigens on MHC I to CD8+ T cells, in 
contrast to DCs exposed to heat-inactivated IAV210. Hence, papers I and II were 
designed to follow up on the published observation by visualising where IAV traffics 
to upon entry into human DCs using super resolution microscopy (paper I), and by 
assessing whether mature DCs are also susceptible to IAV infection (paper II). 
However, the limitation of in vitro studies using blood DCs prompted us to investigate 
lung DCs that may be more relevant in the context of respiratory virus infection. We 
first characterised lung MNPs at steady state (paper III) and observed differences in 
subpopulations of monocytes and DCs in blood and lungs. Using this knowledge, we 
next investigated how hantavirus infection affects MNP subsets in blood and lungs of 
acute HFRS patients (paper IV). Key findings are highlighted in this section, followed 
by a general discussion on how the data fits into the existing literature. Detailed 
information can be obtained in the original papers (I–IV). 
6.1 SUBCELLULAR TRAFFICKING OF IAV IN HUMAN DCs (PAPER I) 
DCs are highly reliant on the endocytic machinery in order to sample the surrounding 
for presence of pathogens. Regulation of endocytic pH in DCs ensures that there is 
a balance between the destructive capacity of proteolytic enzymes and the ability to 
conserve antigenic peptides318,319. Like many viruses, IAV exploits this endocytic 
machinery in order to gain access into target cells320. Studies investigating the 
events following uptake and subcellular trafficking of IAV have mostly used animal or 
human cell lines such as MDCK cells and A549 cells166,321. Upon binding and 
internalisation, virions are delivered to early endosomes characterized by proteins 
such as EEA1 and Rab5. The virus then progresses to late endosomes or 
lysosomes, expressing Lamp1 and Rab7, where the lower pH allows membrane 
fusion and release of viral RNP into the cytoplasm. Although DCs have been shown 
to be susceptible to IAV infection, it has yet to be investigated whether the virus 
traffics in a similar manner in these cells with a unique endocytic machinery. We took 
advantage of STED imaging to generate valuable insight into the nanoscale 
organisation of viral and cellular proteins317.  
In this study, in vitro-generated MDDCs were pulsed with IAV at an MOI of 25 for 1 
hour at 4°C, and replication was allowed to proceed after washing off excess virus 
by incubating the cells at 37°C. The cells were then fixed after 0, 5, 10, 15 and 30 
min to track the spatiotemporal localisation of IAV in different endosomal 
compartments. Cells were then stained with antibodies against IAV NP, HLA-DR and 
EEA1 or LAMP1 to identify early endosomes or late endosomes/lysosomes 
respectively. Using STED microscopy with deconvolution, we were able to improve 
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the resolution significantly. We measured the degree of spatial coincidence in the 
deconvolved STED images by using an automated analysis programme where 
colocalisation was defined by an overlap of 10% between the fluorescent signals of 
IAV NP (parent) and EEA1 or LAMP1 (child). We found that the peak of IAV NP 
colocalising with EEA1+ early endosomes occurred 5 minutes after infection, 
whereas IAV NP colocalises with LAMP1+ late endosomes/lysosomes at a maximum 
after 15 minutes (Figure 12). Compared to epithelial cells where fusion of IAV occurs 
after 8 minutes, subcellular trafficking of IAV in human DCs follows a more delayed 
kinetics, in line with preservation of antigens for presentation to T cells. 
 
 
The novel method of investigating viral trafficking in human DCs by three-colour 
STED microscopy provides a platform for further investigations. Continuous efforts 
are focused on dissecting the machinery of how IAV infection in DCs impairs antigen 
presentation on MHC I, whereas exposure to heat-inactivated virus permits efficient 
presentation of antigens to CD8 T cells210. By immuno-labelling proteins involved in 
the MHC I processing machinery, differences between DCs exposed to replicating or 
heat-inactivated virus could be compared to uncover possible mechanisms of 
impairment. 
Figure 12. IAV traffics to early and late endosomes in human MDDCs. (a) STED images of a 
human MDDC exposed to IAV for 5 min (top panel) and stained with antibodies against IAV NP 
(green), HLA-DR (blue) and EEA1 (red), or IAV for 15 min (bottom panel) and stained with 
antibodies against IAV NP (green). Scale bar, 5 µm. (b) Bar graphs summarise the percentages of 
total IAV NP+ signals that colocalise with EEA1 (top panel) or LAMP1 (bottom panel) with median 
values indicated by a red line. Statistical differences were assessed using an unpaired t test: ** p 
< 0.01, *** p < 0.001, **** p < 0.0001 n.s., not significant.  
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6.2 DIFFERENTIAL SUSCEPTIBILITY OF MDDCs AND CD1c+ MDCs TO IAV 
(PAPER II) 
In vitro-generated MDDCs are frequently used in studies investigating human DCs, 
due to the rarity of primary human DCs. In this study, we investigated the role of 
TLR-induced DC maturation in modulating the susceptibility of MDDCs to IAV 
infection and in parallel compared with primary CD1c+ MDCs. This is to simulate how 
in the lungs, blood monocytes and DCs infiltrate the lungs upon induction of an 
inflammatory state. DCs may have received other stimuli and undergone maturation 
prior to encountering IAV. Mature DCs can continue to capture, process, and present 
antigens via receptor-mediated endocytosis92. Thus, it is of relevance to understand 
how mature DCs are affected by IAV infection.  
In this published study, we showed that both MDDCs and CD1c+ MDCs were 
differentially susceptible to IAV infection, depending on how the cells were stimulated 
(Figure 13a). MDDCs infected with IAV for 24 hours after being stimulated overnight 
with LPS or poly(I:C) showed a significantly reduced infection frequency compared 
to unstimulated MDDCs. In contrast, CD1c+ MDCs infected with IAV after stimulation 
with poly(I:C) and 7/8L were less susceptible to infection compared to unstimulated 
CD1c+ MDCs.  
 
As IAV is sensitive to type I IFN-mediated responses, we investigated whether the 
reduced susceptibility to infection could be related to the differential capacity of DCs 
to produce type I IFNs upon stimulation with TLR ligands. Indeed, MDDCs 
stimulated with LPS or poly(I:C) produced detectable levels of biologically active IFN-
Figure 13. Mature MDDCs and CD1c+ MDCs are differentially susceptible to IAV. (a) Bar 
graphs show mean±SEM percentage of IAV NP+  MDDCs (left panel) or CD1c+ MDCs (right panel) 
(n = 26). (b) Bar graphs show mean±SEM levels of biologically active type I IFNs in supernatants 
collected from MDDCs (left panel) or CD1c+ MDCs (right panel)  (n = 11). 
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α unlike unstimulated or 7/8L-stimulated MDDCs (Figure 13b). On the other hand, 
CD1c+ MDCs stimulated with poly(I:C) or 7/8L produced higher levels of IFN-α than 
unstimulated or LPS-stimulated CD1c+ MDCs. This observation was further 
confirmed with experiments using a cocktail of blocking antibodies against IFN-α, 
IFN-β and the IFN receptor, which reversed the protective effect against IAV 
conferred on mature DCs. 
To understand why MDDCs and CD1c+ MDCs responded differently to TLR ligands 
at the molecular level, we performed qRT-PCR on pure, sorted populations of 
MDDCs and CD1c+ MDCs. Strikingly, MDDCs and CD1c+ MDCs exhibited different 
mRNA expression levels of adaptor proteins TRIF and MyD88. MDDCs expressed 
markedly higher levels of TRIF compared to MDCs, whereas CD1c+ MDCs 
expressed higher levels of MyD88 than MDDCs. Higher TRIF expression in MDDCs 
could explain the differences we observed with LPS stimulation, because the 
LPS/TLR4/TRIF axis is responsible for inducing type I IFN98. Similarly, higher MyD88 
expression in CD1c+ MDCs could explain the difference we observed with 7/8L 
stimulation, as TLR7/8 utilises the MyD88 adaptor molecule for its downstream 
effects, including induction of type I IFNs98. The differences at RNA level were 
functionally confirmed using TRIF siRNA on MDDCs, which depleted the RNA levels 
of TRIF, resulting in LPS- or poly(I:C)-stimulated MDDCs to be equally susceptible to 
IAV as unstimulated MDDCs. Using a peptide inhibitor specific to MyD88 on CD1c+ 
MDCs also resulted in lower levels of IFN-β produced. The findings in this study 
underline the inherent, genetic differences between in vitro-generated MDDCs and 
bona fide CD1c+ MDCs that influence their ability to respond to danger signals and 
produce type I IFNs. Thus, the predominance of a specific population at the site of 
infection, e.g. inflammatory MDDCs that have been reported in vivo in humans, may 
alter the outcome of how well these DCs can go on to activate T cells, as infected 
DCs are less efficient at cross-presentation210. 
6.3 CHARACTERISATION OF DCs IN HUMAN LUNGS AT STEADY STATE 
(PAPER III) 
Studies in mouse models illustrate that DCs play distinct roles depending on tissue 
location, as the local microenvironment in the lungs may fine-tune the functionality of 
DCs322. Lung DCs in mice have been demonstrated to be important in resolving 
respiratory viral infections but have also been implicated in lung 
immunopathology323-325. However, the translation of these findings to humans has 
been limited due to the inaccessibility of human lung tissue coupled with the rarity of 
DCs in tissue. Pioneering studies relied on morphology and expression of single 
markers such as HLA-DR and CD11c using immunohistochemistry. However, the 
identification of DCs in tissue is complicated by presence of macrophages and 
monocyte-derived cells expressing similar markers. Thus, to carefully characterise 
populations of monocytes and DCs in the lungs at steady state, we performed 
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bronchoscopies on healthy, non-smoking individuals from which we obtained 
mucosal tissue (EBB), as well as two sequential lavages sampling the proximal and 
distal airways (BW and BAL respectively). 
In this published study, we performed multi-colour flow cytometry on PBMCs, BW, 
BAL and EBB cells from 20 healthy subjects. In addition to a majority population of 
highly autofluorescent alveolar macrophages in the airways, we identified six 
additional populations of MNPs in the proximal and distal airways (Figure 14a). 
Unlike in blood, the airways were enriched with CD14+CD16+ monocyte-derived 
cells. We were unable to ascertain whether these cells are monocyte-derived 
macrophages, as they did not upregulate CD163, the macrophage scavenger 
receptor. Further, we expected them to downregulate CCR2, as has been shown in 
monocyte-derived macrophages in the lungs of rhesus macaques326 but this was 
also not the case. To further investigate the identity of monocytes in the airways, we 
stained for other typical macrophage markers, but could not detect an upregulation 
of CD64 or CD68 on monocyte populations in the airways as compared to blood 
(unpublished data). In enzymatically-digested EBBs, we could only identify classical 
monocytes, CD1c+ MDCs, CD141+ MDCs and PDCs.  
 
 
Figure 14. Identification of lung MNPs in BAL. (a) Flow cytometry plots show the gating strategy 
to identify monocyte populations and DC populations in the lungs. One representative donor is 
shown out of 19 healthy subjects. (b) Dot plot of CD14 against CD1c (left panel) depicts CD1c+ 
CD14+ cells (green dots) and CD1c+ MDCs (coral dots) that were backgated to the parent gate 
consisting of total HLA-DR+lin- cells (gray dots). Histogram (right panel) depicts CD14 expression 
on CD1c+ MDC (coral), CD1c+ CD14+ monocytes (dashed green line) and CD1c- CD14+ 
monocytes (green line) (n=19).  (c) Histograms show CD206 expression on CD1c+ MDC (left 
panel) and CD141+ MDC (right panel) in PBMCs (grey) and BAL (coral or maroon). 
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Unlike blood MNPs, the populations identified in the lungs also express different 
phenotypic markers. For instance, a subpopulation of CD14+CD16- classical 
monocytes in the airways upregulated CD1c, perhaps indicative of their 
differentiation into DCs140 (Figure 14b). Our functional data suggest that upon 
stimulation with TLR ligands, the CD1c+ monocyte-derived cells responded in a 
similar fashion to CD14+ monocytes than to CD1c+ MDCs (data not shown). 
However, the possibility that they may be CD1c+ MDCs that have upregulated CD14 
cannot be completely excluded. Further transcriptomics analysis of sorted cell 
populations may be necessary to elucidate this. CD1c+ MDCs in BAL also express 
mannose receptor (CD206), unlike their blood counterparts, providing an additional 
endocytic receptor for antigen sensing in the lungs (Figure 14c).  
CD1c+ MDCs in BW and BAL also expressed a semi-mature phenotype, with higher 
expression of CD86 and CCR7 compared to blood CD1c+ MDCs. This could indicate 
that MNPs lining the airways have already encountered self antigens or harmless 
particles, and perhaps responded in a tolerogenic manner, as the subjects included 
in this study were healthy and had no signs of airway inflammation. In contrast, all 
MNPs identified in the mucosal biopsies were relatively immature. Finally, we 
investigated whether respiratory MNPs could respond in an inflammatory manner if 
challenged with pathogens. The induction of a cytokine storm resulting in severe 
inflammation in the lungs has also been observed in human lungs during pandemic 
influenza184. To simulate a microbial exposure in ex vivo cultures, we stimulated bulk 
populations of PBMCs and BAL cells with a panel of TLR ligands for TLR3, TLR4 
and TLR7/8 to mimic bacterial or viral challenge. Blood monocytes were superior in 
producing the pro-inflammatory cytokine TNF compared to BAL monocytes. 
However, CD1c+ MDCs in BAL were better at producing TNF than blood CD1c+ 
MDCs. This further illustrates that lung MNPs are distinct from blood MNPs due to 
local signals from the microenvironment. In conclusion, we have characterised lung 
monocytes and DCs, to provide a clearer baseline for future studies investigating the 
role of lung MNPs in pathological conditions.  
6.4 LOSS OF DCs IN PERIPHERAL BLOOD OF ACUTE HFRS PATIENTS 
(PAPER IV) 
An exaggerated immune response has been suggested to contribute to 
pathogenesis of hantavirus infections, as the viruses do not cause direct cytopathic 
effects. In particular, an expansion of effector cells such as NK cells and CTLs in the 
blood and lungs has been implicated to attack endothelial cells and cause capillary 
leakage, a hallmark of hantavirus pathogenesis262,294,309. DCs and monocytes can 
regulate the activation of other immune cells, yet little is known on the role of 
monocytes and DCs during hantavirus infection. In this study, we collected 
longitudinal blood samples from HFRS patients confirmed to be infected with PUUV, 
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the endemic hantavirus strain in Sweden. Additionally, we collected lung biopsies, 
embedded in GMA for tissue sectioning and immunohistochemical analysis.  
Strikingly, there was a pronounced loss of blood monocytes and especially DCs 
during the acute phase of disease (Figure 15a). The numbers of blood MNPs was 
inversely correlated to viral load detected in plasma, as the cell numbers returned to 
normal values during the convalescence phase of disease when virus could no 
longer be detected by PCR. The low numbers of MNPs in blood during acute HFRS 
could be explained by cell death or cell migration. As NK cells and CTLs are 
activated in the blood during hantavirus infections263,294, this immune-mediated 
cytotoxicity may inadvertently kill off monocytes and DCs in the blood.  
 
The alternative hypothesis is that blood monocytes and DCs have migrated out of 
circulation to lymphoid tissues or peripheral tissues. Indeed, the few monocytes  and 
DCs still present in blood during acute HFRS upregulated CCR7, a lymph node-
homing chemokine receptor for DCs, also important for tissue-homing in 
monocytes327. In tissue sections of lung biopsies taken during the acute phase of 
disease, we detected higher levels of HLA-DR, CD11c and CD123, as compared to 
biopsies from uninfected controls, indicating an infiltration of MNPs into the lungs 
Figure 15. Massive loss of blood DCs in acute HFRS patients concurrent with infiltration of 
HLA-DR+ cells in the lungs. (a) Bar graphs depict mean±SD absolute cell numbers of DC 
subsets in blood of HFRS patients (coloured bars) compared to uninfected controls (white bars). 
Differences in mean absolute number of MDCs were assessed using Poisson regression. (b) 
Representative images of endobronchial biopsies revealing high numbers of HLA-DR+ cells in 
HFRS patients (n=5), as compared to uninfected controls (n=5) are shown. Specific staining is 
shown in red and cell nuclei counterstained with hematoxylin in blue. Visualization was performed 
using immunohistochemistry, and percentage of positive stained area was quantified. Scale bar, 
100 µm. (c) Bar graph summarizes mean±SD percentage of HLA-DR stained area of all subjects. 
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(Figure 15b). The increase in HLA-DR+ staining in lung sections from acute HFRS 
was statistically significant compared to uninfected controls (Figure 15c). However, 
since the lung sections were limited to staining with single markers, it is also possible 
that other cells such as T cells or NK cells that can upregulate HLA-DR upon 
activation, thus contributing to the increased number of HLA-DR+ cells observed. An 
evaluation of similar markers by multi-colour flow cytometry on digested lung 
biopsies or BAL cells as done in paper III would provide a more complete depiction 
on the identities of cell infiltrates into the lungs of hantavirus-infected patients. 
Nevertheless, an influx of monocyte-derived cells and DCs in the lungs might explain 
the reported activated phenotype of CD8+ T cells in the lungs during acute HFRS, 
correlating to respiratory symptoms in patients263,309. By mapping the movement of 
monocytes and DCs during an acute viral disease in humans, we learn more about 
the potential roles of specific subsets based on their tissue locations during the 
course of disease. 
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7 CONCLUSIONS 
”Savoir pour prévoir, afin de pouvoir” – Auguste Comte 
The studies in this thesis were designed to improve our understanding of how DCs, 
key players in modulating our immune response, are involved during respiratory viral 
infections in humans. A vast majority of our current understanding of the interaction 
between DCs and viruses is derived from studies in animal models, leaving a big 
gap of knowledge to be filled where human immunology is concerned. Furthermore, 
most human immune studies have focused on cells in circulation. Immunologists are 
shifting their attention towards tissue specificity, as immune cells residing in 
peripheral tissues have distinct and locally important traits than those in 
circulation328-330. Working with rare immune cells in human blood and lungs prove to 
be challenging, with limitations on what can be done with the few cells that can be 
obtained. Basic research using human immune cells, even if at first necessarily 
descriptive, is essential in generating important insights on whether similar monocyte 
and DC populations that have been described in mice also exist in humans, both at 
steady state and in disease. By extending our body of knowledge on how our human 
immune system functions, we can begin to translate important findings in mice to 
eventually developing novel strategies against respiratory viruses such as influenza 
and hantavirus that cause severe disease in humans.  
In summary, the work presented in this thesis support the following four general 
conclusions: 
(1) IAV traffics in human DCs via early and late endosomes, similar to what has 
been documented in epithelial cells, albeit at a more delayed pace (paper I).   
(2) DCs derived from monocytes are inherently different from bona fide DCs, 
illustrated by their distinct capacity to produce protective antivirals upon 
recognition of pathogenic signals (paper II). 
(3) Monocytes and DCs are patrolling our airways and lung tissue during healthy 
conditions, and they have slightly different phenotypes and functions than their 
blood counterparts (paper III). 
(4) During acute disease, there are fewer monocytes and DCs circulating in the 
blood of hantavirus-infected patients, as they may be migrating towards the lungs 
where the virus first arrives, or lymph nodes where they can activate other 
adaptive immune cells (paper IV). 
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8 FUTURE DIRECTIONS 
Based on the current findings presented in this thesis, there are still many 
unanswered questions that we can continue to explore.  
Using the platform that we have established in paper I for performing three-colour 
STED microscopy, we can investigate the mechanism for impairment of antigen 
presentation in IAV-infected DCs by visualising IAV proteins relative to components 
of the host cell machinery. A key hypothesis is that defective ribosomal products 
(DRiPs), a side product of newly synthesised viral proteins, may become 
sequestered in DC aggresome-like induced structures (DALIS), thus limiting the 
amount viral antigen available on MHC I331,332. Hence, the observed impairment can 
potentially be overcome if DCs are allowed to be infected for a longer time, as DALIS 
structures are transient and dissociate after 24 hours. The delay in antigen 
presentation may be a strategy by DCs to conserve viral antigens until they complete 
their maturation process and have arrived in draining lymph nodes. 
Following up on the findings of paper II, we can investigate whether mature DCs that 
are still susceptible to IAV infection could also have an impaired capacity to present 
antigen. The maturation programme may override the viruses’ ability to disrupt 
efficient antigen presentation. As monocyte-derived cells such as TNF/iNOS-
producing DCs (TIP-DCs) have been described to infiltrate the lungs during IAV 
infection in mice214, it may be worth assessing whether viral replication takes place in 
human MDDCs in vivo and if so, whether these cells retain their ability to activate 
CD8+ T cells. 
Our characterisation of lung MNPs in paper III opened up Pandora’s box as we 
contemplate the division of labour between the subsets of monocyte-derived cells 
and DCs residing in the lungs at steady state. On-going discussions are focused on 
how these cells lining the airways squeeze through the epithelial barrier and whether 
they can cross back to migrate to draining lymph nodes. Another interesting aspect 
of capturing a snapshot of all cells at one time point in the lungs, is how we can 
distinguish the lung-resident cells versus newly infiltrating cells, as there will be a 
mixed population of cells especially during inflammation. 
Finally, we would like to elucidate the mechanism for the loss of MNPs in the blood 
of acute HFRS patients described in paper IV, by continuing on in vitro infection 
experiments where we can include more chemokine receptors and integrins that can 
reveal whether the cells are migrating towards specific tissues, such as the lungs or 
the kidneys. In future HFRS patients, we can sort out individual populations of lung 
MNPs and perform functional experiments and transcriptomics analysis to gain even 
more information on these cells. Additionally, urine from patients may be collected to 
investigate if monocytes and DCs infiltrate the kidneys during acute disease. 
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The study of the human immune system, particularly in the context of infectious 
diseases, has its own unique challenges but can have an important impact in the 
development of novel preventive and treatment strategies that can be applied to 
society. While we have learnt a lot from mouse studies, there are obvious limitations 
in terms of their evolutionary distance from humans. As described by David 
Masopust, laboratory mice are bred in such clean environments that they no longer 
resemble the human immune system, because humans do not live in sterile 
environments333. Bridging the gap between advanced mouse studies and human 
clinical trials requires a deeper understanding of how human immune cells behave 
and function at a basic level, both in health and disease. In order to achieve this, 
more collaborations between scientists and surgeons with access to precious human 
tissues/organs need to be established and prioritised. To paraphrase the French 
philosopher Auguste Comte, by expanding our wealth of knowledge, we can predict 
how our enemies may launch their attack against us, and this gives us the artillery to 
protect ourselves and prevent a repeat of devastating events.   
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